Occult viral hepatitis and noncirrhotic hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 100, Issue 8, 2005, Pages 1754-1757

  Gordon, Stuart C ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; VIRUS DNA; VIRUS RNA; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER RISK; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG INHIBITION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; GENETICS; HEPATITIS C VIRUS; LIVER TUMOR; NOTE; PHYSIOLOGY; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; VIRUS INTEGRATION;

EID: 25644437123     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50483.x     Document Type: Review

References (25)

1. Toberson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-86.
2. Marrero JA, Lok ASF. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology 2004;126:347-50.
3. Pollicino T, Squadrito G, Cezenzia G, et al. Hepatitis B virus (HBV) maintains its pro-oncogenic properties in case of occult HBV infection. Gastroenterology 2004; 126:102-10.
4. Castillo I, Pardo M, Bartolome J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistent abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
5. Castillo I, Rodriguez-Iñigo E, Bartolome J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682-5.
6. Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virology 2004;78:5867-74.
7. Radkowski M, Gallegos-Orozco JF, Jablonski J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-14.
8. Feld JJ, Liang TK. HCV persistence: Cure is still a four letter word. Hepatology 2005;41:23-5.
9. Tamori A, Nishiguchi S, Shiomi S, et al. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 2005;100:1748-53.
10. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616-22.
11. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 2003;23:593-6.
12. Bralet MP, Regimbeau JM, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
13. Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000;9:213-6.
14. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127:835-850.
15. McHutchison JG, Poynard T, Esteban-Mur R, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-93.
16. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
17. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis dela virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420-6.
18. Propst T, Propst A, Dietze O, et al. Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol 1994;21:1006-11.
19. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.
20. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.
21. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;5:1303-13.
22. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004;127:S62-S71.
23. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
24. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004;127:S17-S26.
25. Chang MH, Chen CJ, Lai MS, et al. Universal vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-959.